Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now.

On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level. The firm maintained its Buy rating on the stock.

Mila Supinskaya Glashchenko/Shutterstock.com

Goldman Sachs reflected on the FDA approval call regarding Viridian’s Lumvoa, which carries a unique profile for the treatment of thyroid eye disease compared to Tepezza. The firm stated that Lumvoa is more efficient for the improvement of proptosis, and its safety profile is promising. Its dosing regimen is also more convenient, which backs a highly optimistic stance towards its planned commercial launch.

On June 30, Truist also increased its target price on the stock from $35 to $38, which yields more than 100% upside potential. The firm reiterated a Buy rating on the stock, also highlighting Lumvoa’s differentiated profile relative to Tepezza.

Besides that, Truist also noted other commercial factors that give Lumvoa a comparative advantage. These include its focus on underserved markets and parity pricing. The firm projects significant revenue generation by 2027 and its franchise extension through an initiative planned for the first quarter of 2027.

Viridian Therapeutics Inc. (NASDAQ:VRDN) is involved in discovering and selling treatments for rare and serious illnesses. It produces three main therapeutics, which include Veligrotrug, Elegrobart, and anti-thyroid-stimulating hormone receptor. Its portfolio of engineered inhibitors of the neonatal Fc receptor includes VRDN-008 and VRDN-006.

While we acknowledge the risk and potential of VRDN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRDN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1